Xoran Minicat00202
Published November 6, 2013 · Recall initiated: July 27, 2010
Summary
FDA records medical device Class II recall Z-0038-2014, published November 6, 2013 and initiated July 27, 2010. Recalling firm: Xoran Technologies, Inc.; Status: Terminated; Reported quantity: 320; Lot: minicat. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
The MiniCAT CT Scanners subject to this notification failed to meet Xoran's specifications for dose rate of 125 ¿ 3 kVp. These 18 complaints received include dose rates both on the high and low end of Xoran's specifications. See ATTACHMENT 1 for details. (e) A n evaluation of the hazards reasonably related to defect or the failure to comply with the Federal standard; An evaluation of the health ha
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Xoran Technologies, Inc.
- Distributor
- Worldwide Distribution - US nationwide
- Lot
- minicat
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAXoran Minicat00158November 6, 2013
- FDAXoran MiniCAT CT ScannerNovember 6, 2013
- FDAXoran MiniCAT00202November 6, 2013
- FDAXoran MiniCAT CT Scanner ID ENT00001November 6, 2013
- FDAXoran Mini CT ScannerNovember 6, 2013
- FDAWestern Nut Salt Lake City Roasted and Salted Inshell Peanuts, 6 oz (170g). Packaged in OPP (orientedNovember 6, 2013
Questions about this recall
Was Xoran Minicat00202 recalled?
Yes. FDA published recall Z-0038-2014 on November 6, 2013. Reported hazard: The MiniCAT CT Scanners subject to this notification failed to meet Xoran's specifications for dose rate of 125 ¿ 3 kVp. These 18 complaints received include dose rates both on the high and low end of Xoran's specifications. See ATTACHMENT 1 for details. (e) A n evaluation of the hazards reasonably related to defect or the failure to comply with the Federal standard; An evaluation of the health ha
What should I do if I have this product?
Voluntary: Firm initiated · Letter